Login to Your Account


Pharma: Other News To Note


Wednesday, February 20, 2013
• Novartis AG, of Basel, Switzerland, said the FDA approved mTOR inhibitor Zortress (everolimus) for the prophylaxis of organ rejection in adults receiving liver transplants.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription


»